Back to all webinars
Expert Review of ASH 2022
Christian Buske, Paolo Ghia and Shirley D’Sa reflect on the data presented at ASH 2022 that are most relevant for clinical practice, highlighting developments in CAR-T, bispecific antibody, and BTK inhibitor therapies, and more.
Speakers
What’s practice changing in CLL
Fast-forward to:
CLL treatments and overview
643d2d79d48ee4033232f730
ALPINE study: Zanubrutinib vs. ibrutinib in R/R CLL
643e5f6622898a03387ea795
CAPTIVATE study: 5-year follow-up of first-line ibrutinib + venetoclax
643e607b22898a03387ea7a9
GLOW study: First-line ibrutinib + venetoclax vs. chlorambucil + obinutuzumab
643e823822898a03387ea7c0
Potential first-line treatment algorithm
643e833b6356950331f0029b
What’s practice changing in indolent lymphomas
Fast-forward to:
R/R MZL: MAGNOLIA study of zanubrutinib
643e83ddd48ee4033232f87d
Untreated MCL: TRIANGLE study
643e87b792cf06033e70b711
R/R WM: BRUIN study of pirtobrutinib
643e88bf22898a03387ea821
Untreated WM: Venetoclax + ibrutinib
643e8aa692cf06033e70b748
Discussion and audience Q&A
Fast-forward to:
MAGNOLIA results in R/R MZL
643e8d8c92cf06033e70b75b
Biomarkers for CLL with targeted therapy
643e8de422898a03387ea857
Treating TP53-mutated patients with CLL
643e8e27d48ee4033232f8dc
Cardiac toxicity with Ven-Obi
643e8f8a92cf06033e70b767
Role of CAR-T after BKTis in CLL or MCL
643e8fe522898a03387ea875
Role of MRD in CLL
643e902d6356950331f0031c
Role of ASCT in MCL
643e908222898a03387ea889
Summary
No entries